Introduction of HIV drug-resistance testing in clinical practice

AIDS

Volumn 13, Issue 9, 1999, Pages 1007-1014

  Rodríguez Rosado, Rafael ^a   Briones, Carlos ^a   Soriano, Vincent ^a,b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b NONE   (Spain)

Author keywords

Diagnosis; Drug resistance; Highly active antiretroviral therapy; Viral load

Indexed keywords

ABACAVIR; ADEFOVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOVIRIDE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ASSAY; CLINICAL PRACTICE; CROSS RESISTANCE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HIV-1; HUMANS;

EID: 0032808187     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199906180-00001     Document Type: Review

References (47)

1. 1. Lew J, Reichelderfer P, Fowler M, et al. Determinations of levels of HIV type 1 RNA in plasma: reassessment of parameters affecting assay outcome. J Clin Microbiol 1998, 36:1471-1479.
2. 2. Carpenter C, Fischl M, Hammer S, et al. Antiretroviral therapy for HIV infection in 1998. JAMA 1998, 280:78-86.
3. 3. Gazzard B, Moyle G, on behalf of the BHIVA Guidelines Writing Committee. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1998, 352:314-316.
4. 4. Soriano V, Jiménez-Nácher J. Antiretroviral treatment: when to start and what drugs to use?. Med Clin (Barc) 1998, 111:137-141.
5. 5. Schrager L, D'Souza P. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 1998, 280:67-71.
6. 6. Lanier R, Danehower S, Daluge S, et al. Genotypic and phenotypic correlates of response to abacavir (ABC, 1592). Antiviral Ther 1998, 3 (Suppl. 1):36.
7. 7. Deeks S, Parkin N, Petropoulos C, et al. Correlation of baseline phenotypic drug susceptibility with 16 week virologic response in a pilot combination therapy study in HIV-infected patients who failed indinavir therapy. Antiviral Ther 1998, 3 (Suppl. 1):36-37.
8. 8. Zolopa A, Shafer R, Warford A, Montoya J, Katzenstein D, Merigan T. Predictors of antiviral response to SQV/RTV in a clinical cohort who have failed prior Pls: a comparison of clinical characteristics, antiretroviral drug history and HIV genotype. Antiviral Ther 1998, 3 (Suppl. 1):37.
9. 9. Harrigan P, Montaner J, Hogg R, et al. Baseline resistance profile predicts response to RTV/SQV therapy in a community setting. Antiviral Ther 1998, 3 (Suppl. 1):38.
10. 10. Domingo E, Holland J. RNA virus mutations and fitness for survival. Annu Rev Microbiol 1997, 51:151-178.
11. 11. Hirsch M, Conway B, D'Aquila R, et al. Antiretroviral drug resistance testing in adults with HIV infection. JAMA 1998, 279:1984-1991.
12. 12. Roberts N, Craig JC, Sheldon J. Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: theory and practice. AIDS 1998, 12:453-460.
13. 13. Gómez-Cano M, Soriano V. Resistance to antiretroviral drugs. Med Clin (Barc) 1997, 109:546-548.
14. 14. Carrillo A, Stewart K, Sham H, et al. In vitro selection and characterization of HIV type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J Virol 1998, 72:7532-7541.
15. 15. Villalba N, Soriano V, Gómez-Cano M, Castilla J, Mas A, González-Lahoz J. Short-term efficacy and safety of stavudine in pretreated HIV-infected patients. Antiviral Ther 1997, 2:185-189.
16. 16. Friedland A, Paibir S, Srinivas M, et al. Involvement of an active efflux pump in the cellular resistance of antiretroviral nucleoside analogs. Antiviral Res 1998, 37:40.
17. 17. Lee C, Gottesman M, Cardarellir C, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998, 37:3594-3601.
18. 18. Kim R, Fromm F, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998, 101:289-294.
19. 19. Birk M, Sönnerborg A. Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patients. AIDS 1998, 12:2369-2375.
20. 20. Quiñones-Mateu M, Albright J, Mas A, Soriano V, Arts E. Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with group O strains of HIV type 1. J Virol 1998, 72:9002-9015.
21. 21. van der Ende M, Schutten M, Ly TD, Gruters RA, Osterhaus AA. HIV-2 infection in 12 European residents: virus characteristics and disease progression. AIDS 1996, 10:1649-1655.
22. 22. Palmer S, Alaeus A, Albert J, Cox S. Drug susceptibility of sub-types A, B, C, D, and E HIV type 1 primary isolates. AIDS Res Hum Retroviruses 1998, 14:157-162.
23. 23. Cox S, Aperia K, Albert J, Wahren B. Comparison of the sensitivities of primary isolates of HIV type 2 and HIV type 1 to antiviral drugs and drug combinations. AIDS Res Hum Retroviruses 1994, 12:1725-1729.
24. 24. Descamps D, Collin G, Letourneur F, et al. Susceptibility of HIV-1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analysis. J Virol 1998, 71:8893-8898.
25. 25. Quiñones-Mateu M, Soriano V, Domingo E, Menéndez-Arias L. Characterization of the reverse transcriptase of a HIV type 1 group O isolate. Virology 1997, 236:364-373.
26. 26. St Clair M, Martin J, Tudor-Williams G, et al. Resistance to dd1 and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991, 253:1557-1559.
27. 27. Larder B, Kemp A, Harrigan P. Potential mechanism for sustained antiretroviral efficacy of AZT plus 3TC combination therapy. Science 1995, 269:696-699.
28. 28. Wainberg M, Miller M, Quan Y, et al. The M184V substitution in RT moderately increases sensitivity of HIV-1 to PMPA. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, January 1998 [abstract 680].
29. 29. Kemp S, Shi C, Bloor S, Harrigan P, Mellors J, Larder B. A novel polymorphism at codon 333 of HIV type 1 RT can facilitate dual resistance to zidovudine and 3TC. J Virol 1998, 72:5093-5098.
30. 30. Dealaney S, Zhung N, McQueen P, Cooper D. Emergence of drug-resistant HIV-1 strains from patients on long term dd1 therapy. 12th World AIDS Conference. Geneva, July 1998 [abstract 41.224].
31. 31. Gómez-Cano M, Rubio A, Puig T, et al. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. AIDS 1998, 12:1015-1020.
32. 32. Schmit J-C, Van Laethem K, Ruiz L, et al. Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. AIDS 1998, 12:2007-2015.
33. 33. Bloor S, Hertogs K, Desmet R, Pauwels R, Larder B. Virological basis for HIV-1 resistance to stavudine investigated by analysis of clinical samples. Antiviral Ther 1998, 3 (Suppl. 1):13-14.
34. 34. Whitcomb J, Limoli K, Wrin T, et al. Phenotypic and genotypic analysis of stavudine-resistant isolates of HIV-1. Antiviral Ther 1998, 3 (Suppl. 1):14-15.
35. 35. De Jong J, Jurriaans S, Goudsmit J, et al. Insertion of two amino acids in RT during antiretroviral combination therapy: implications for resistance against nucleoside RT inhibitors. Antiviral Ther 1998, 3 (Suppl. 1):15.
36. 36. Winters M, Coolley K, Girard Y, et al. A 6-basepair insert in the RT gene of HIV-1 confers resistance to multiple nucleoside inhibitors. J Clin Invest 1998, 102:1769-1775.
37. 37. De Antoni A, Foli A, Lisziewicz J, Lori F. Mutations in the pol gene of HIV type 1 in infected patients receiving didanosine and hydroxiurea combination therapy. J Infect Dis 1997, 176:899-903.
38. 38. Tamalet C, Izopet J, Koch N, Fantini J, Yahi N. Stable rearrangements of the β3-β4 hairpin loop of HIV-1 RT in plasma viruses from patients receiving combination therapy. AIDS 1998, 12:F161-F166.
39. 39. Soriano V, Pérez-Olmeda M, Gómez-Cano M, Briones C, González-Lihoz J. Prevalence of the T69SSS insertion in HIV+ patients under antiretroviral therapy. International Conference on the Discovery and Clinical Development of Antiretroviral Therapies, St Thomas, December 1998 [abstract 49]. Antiviral Ther 1998, 3 (Suppl. 5):50.
40. 40. García-Lerma G, Yamamoto S, Gómez-Cano M, Soriano V, Folks L, Heneine W. Measurement of HIV type 1 plasma virus load based in reverse transcriptase activity (RT): evidence of variabilities in levels of virion-associated RT. J Infect Dis 1998, 177:1221-1229.
41. 41. Heneine W, García-Lerma G, Vázquez-Rosales J, et al. A novel non-culture-based approach for the rapid analysis of phenotypic resistance to RTIs of HIV-1 from plasma. Antiviral Ther 1998, 3 (Suppl. 1):42-43.
42. 42. García-Lerma G, Weinstock H, Stang H, et-al. Identification and characterization of a novel multidrug resistance mutation (Q151L) in drug-naive HIV-1 seroconverters. Antiviral Ther 1998, 3 (Suppl. 1):85.
43. 43. Rodríguez-Rosado R, Jiménez-Nácher I, Soriano V, Anton P, González-Lahoz J. Virological failure and adherence to antiretroviral therapy in HIV-infected patients [letter]. AIDS 1998, 12:1112-1113.
44. 44. Clevenberg P. The French VIRADAPT study. 4th International Congress on Drug Therapy n HIV Infection. Glasgow, November 1998 [abstract LB 5].
45. 45. Wainberg M, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998, 279:1977-1983.
46. 46. Imrie A, Beveridge A, Genn W, Vizzard J, Cooper D. Transmission of HIV type 1 resistant to nevirapine and zidovudine: Sydney Primary HIV Infection Study Group. J Infect Dis 1997, 175:1502-1506.
47. 47. Hecht F, Grant R, Petropoulos C, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998, 339:307-311.